PMID- 23637544
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130503
LR  - 20240322
IS  - 1178-6981 (Print)
IS  - 1178-6981 (Electronic)
IS  - 1178-6981 (Linking)
VI  - 5
DP  - 2013
TI  - Comparison of health care resource utilization and costs among patients with GERD 
      on once-daily or twice-daily proton pump inhibitor therapy.
PG  - 161-9
LID - 10.2147/CEOR.S41189 [doi]
AB  - BACKGROUND: The purpose of this study was to assess differences in health care 
      resource utilization and costs associated with once-daily and twice-daily proton 
      pump inhibitor (PPI) therapy. Most patients with gastroesophageal reflux disease 
      (GERD) achieve symptom control on once-daily PPI therapy, but approximately 
      20%-30% require twice-daily dosing. METHODS: Patients were >/=18 years of age with 
      at least one medical claim for GERD and at least two PPI claims from HealthCore's 
      Integrated Research Database (HIRD(SM)) during 2004-2009. Patients were 
      continuously eligible for 12 months before and after the index date (date of 
      first PPI claim). Based on PPI dosing throughout the post-index period (quantity 
      of medication dispensed/number of days supply), patients were classified as 
      once-daily (dose </= 1.5 pills per day) or twice-daily (>/=1.5) PPI users. RESULTS: 
      The study cohort included 248,386 patients with GERD (mean age 52.8 +/- 13.93 
      years, 56% females) of whom 90% were once-daily and 10% were twice-daily PPI 
      users. The Deyo-Charlson Comorbidity Index for once-daily and twice-daily PPI 
      users was 0.70 +/- 1.37 and 0.89 +/- 1.54, respectively (P < 0.05). More once-daily 
      patients had claims for Barrett's esophagus (5% versus 2%, P < 0.0001) than 
      twice-daily patients. Post-index, higher proportions of twice-daily patients had 
      at least one GERD-related inpatient visit (7% versus 5%), outpatient visit (60% 
      versus 49%), and office visit (48% versus 38%) versus once-daily patients (P < 
      0.0001). Mean total GERD-related health care costs were $2065 +/- $6636 versus 
      $3749 +/- $11,081 for once-daily and twice-daily PPI users, respectively (P < 
      0.0001). CONCLUSION: Patients receiving twice-daily PPI therapy were likely to 
      have more comorbid conditions and greater health care utilization and overall 
      costs compared with patients using once-daily PPI therapy.
FAU - Mody, Reema
AU  - Mody R
AD  - Takeda Pharmaceuticals International Inc, Deerfield, IL.
FAU - Eisenberg, Debra
AU  - Eisenberg D
FAU - Hou, Likun
AU  - Hou L
FAU - Kamat, Siddhesh
AU  - Kamat S
FAU - Singer, Joseph
AU  - Singer J
FAU - Gerson, Lauren B
AU  - Gerson LB
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - New Zealand
TA  - Clinicoecon Outcomes Res
JT  - ClinicoEconomics and outcomes research : CEOR
JID - 101560564
PMC - PMC3639021
OTO - NOTNLM
OT  - database analysis
OT  - gastroesophageal reflux disease
OT  - health care resource utilization
OT  - proton pump inhibitors
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
PMCR- 2013/04/22
CRDT- 2013/05/03 06:00
PHST- 2013/05/03 06:00 [entrez]
PHST- 2013/05/03 06:00 [pubmed]
PHST- 2013/05/03 06:01 [medline]
PHST- 2013/04/22 00:00 [pmc-release]
AID - ceor-5-161 [pii]
AID - 10.2147/CEOR.S41189 [doi]
PST - epublish
SO  - Clinicoecon Outcomes Res. 2013 Apr 22;5:161-9. doi: 10.2147/CEOR.S41189. Print 
      2013.